MiNK Therapeutics, Inc. (INKT) Earnings
MiNK Therapeutics, Inc. is expected to report next earnings on August 13, 2026 (in NaN days), with a consensus EPS estimate of $-0.60. INKT has beaten EPS estimates in 7 of its last 12 reported quarters (average surprise -14.3% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 15, 2026 | $-0.77 | $-0.57 | +26.0% | — | — |
| Nov 14, 2025 | $-0.86 | $-0.65 | +24.4% | — | — |
| Aug 14, 2025 | $-0.55 | $-1.06 | -92.7% | — | — |
| May 15, 2025 | $-0.61 | $-0.70 | -14.8% | — | — |
| Mar 18, 2025 | $-0.50 | $-0.62 | -24.0% | — | — |
| Nov 14, 2024 | $-0.80 | $-0.50 | +37.5% | — | — |
| Mar 21, 2024 | $-1.50 | $-1.60 | -6.7% | $-11.7B | — |
| Nov 9, 2023 | $-1.80 | $-1.50 | +16.7% | — | — |
| Aug 10, 2023 | $-1.90 | $-1.80 | +5.3% | — | — |
| May 11, 2023 | $-2.40 | $-1.70 | +29.2% | $11.7B | — |
| Mar 21, 2023 | $-2.10 | $-2.30 | -9.5% | $2.7B | — |
| Nov 3, 2022 | $-2.30 | $-1.90 | +17.4% | $1.6B | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 15, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Scientific & Clinical Data Progress * Presented data at four major international scientific conferences in Q1 2026: pulmonary fibrosis findings at the Keystone Symposium (February), Phase II data in refractory gastric cancer at AACR (April), and mechanistic data on context-dependent IMKT cell immune activity at ASGCT (May) * At AACR, the investigator-sponsored Phase II trial in heavily pretreated checkpoint-refractory gastroesophageal cancer reported median overall survival exceeding 23 months in the immune-primed cohort, with durable long-term survival observed across multiple tumor types including gastric cancer, thymoma, renal cell carcinoma, and germ cell cancers * ASGCT presentations confirmed that the same unmodified allogeneic 797 product produces distinct context-dependent immune outputs: Th1-oriented cytotoxic anti-tumor activity in cancer, and inflammation-restoring immune signaling in severe lung injury/ARDS, without requiring disease-specific modification - Key Program Initiations * Announced the initiation of a randomized Phase II trial of 797 + standard of care versus placebo + standard of care for patients meeting global ARDS criteria; the trial uses a seamless Phase 2-3 design to enable rapid transition from signal validation to registrational development if results are positive * The ARDS trial is conducted in partnership with First Lviv Territorial Medical Union and Unbroken Ukraine, approved by both the Ukrainian Ministry of Health and U.S. FDA, and leverages existing clinical infrastructure in Ukraine to evaluate the therapy in a relevant population of wartime trauma patients with complex immune dysfunction and infections * Entered a collaboration with See Further to advance a FRAME-targeted CAR-engineered IMKT cell therapy for pediatric cancers, providing non-dilutive funding for IND-enabling activities while retaining potential downstream commercial participation - Platform Advantages * 797 is an off-the-shelf IMKT cell therapy that does not require lymphodepletion or HLA matching, with a favorable safety profile observed in ~100 treated patients to date; it addresses historical cell therapy barriers including manufacturing complexity, scalability, and deployability in acute care settings * Pre-generated clinical material already exists for most ongoing programs, so no substantial future manufacturing capital burn is expected
Guidance
- Cash runway: Mink's current $9.5 million quarter-end cash position is expected to fund operations through at least the next 12 months, including initiation and full execution of the randomized ARDS Phase II trial, maintaining capital efficiency uncommon in the cell therapy sector - Preliminary data release: Preliminary data from the randomized ARDS Phase II trial is expected to be presented in the second half of 2026 - Commercial planning: Full commercial assessment and commercialization plans for ARDS will be released publicly in parallel with Phase II trial data, no later than the second half of 2026 - Gastric cancer program update: An update on the next steps for the refractory gastric cancer program will be provided after additional follow-up matures
Segment performance
Mink Therapeutics is a clinical-stage biotech company focused on IMKT cell therapy development, with no commercial product segments currently generating revenue. All activity is concentrated on advancing the lead candidate 797 across oncology and critical care indications, with no segmented revenue to report.
Risks & headwinds
- All forward-looking statements related to clinical trial results, regulatory approval, and commercial opportunity are subject to inherent risks and uncertainties, detailed in the company's SEC filings - ARDS drug development has historically faced challenges due to biologic heterogeneity of the condition, and prior cell therapy approaches (including MSC therapies) have failed to consistently improve survival in randomized trials, despite favorable safety profiles - The ARDS trial is being conducted in Ukraine during active wartime, which introduces potential operational risks despite the observed high quality of clinical care at partner sites - The company has a limited cash position, and future development activities may require additional financing
Analyst Q&A
Q: How many patients are enrolled in each arm of the ARDS trial, what endpoints will be available in H2 2026, and what is the status of the ImmunityBio combination program for fungal infection?
A: The randomized Phase II portion of the trial will enroll 90 total patients, split 1:1 between 797 plus standard of care and placebo plus standard of care. A seamless expansion to Phase III will be planned based on Phase II effect sizes, with final patient numbers to be released after an upcoming FDA meeting. Key trial endpoints include overall survival, ventilator-free days, and ICU length of stay, with early readouts expected quickly enough to present preliminary data in H2 2026. Next week at ATS, the company will present a case study of 797 combined with ImmunityBio's ANCEVA (N803) in refractory coccidioides (valley fever) fungal pneumonia, a growing unmet need with limited effective treatments. The case demonstrates combined inflammatory modulation and pathogen clearance, building on prior observations that 797 supports both anti-inflammatory activity and immune recovery.
Q: Is there a prospective patient selection biomarker for 797 response, and are there different regulatory requirements for seamless Phase 2-3 in ARDS versus oncology?
A: Emerging biomarkers that stratify ARDS patients by inflammatory state are expected to be predictive of 797 response, and the trial protocol prospectively stratifies patients by these biomarkers to interrogate this relationship, with more data to come as enrollment progresses. The context-dependent adaptive activity of 797 (producing different immune responses based on the disease microenvironment) has been confirmed by ASGCT data, and this mechanistic insight supports development across multiple disease types. The trial is designed to meet global regulatory standards for ARDS, with biomarker stratification built into the statistical plan to improve the ability to detect a treatment effect in the most relevant patient population.
Q: What commercial planning and distribution preparations have been completed, and is non-dilutive financing being pursued for this program?
A: Commercial assessment is already underway, and distribution logistics have been validated: the company has mastered cryopreserved international shipping, even successfully delivering product to Ukraine during wartime, with proprietary logistics processes already in place. ARDS is a large market opportunity: 200,000 annual U.S. cases and 3 million global cases, and reducing ICU length of stay would generate substantial systemic healthcare cost savings. Full commercial plans and market analysis will be released publicly in parallel with Phase II data in H2 2026.